AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19692802
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (steroid and control)
Trial: 16987866
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg per day for 48 weeks)
Trial: 16987866
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with lamivudine (100 mg per day for 20 weeks) followed by interferon‐alpha‐2b (5 million units three times per week for 4 weeks, then 5 million units three times per week for another 24 weeks)
Trial: 10927061
Drug: Modified hysterosalpingography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified hysterosalpingography (1-2 mL of water-soluble contrast medium followed by 10 mL of saline)
Trial: 8829934
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with a propofol and alfentanil mixture
Trial: 2003707
Drug: Single cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single cycle of perioperative chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin)
Trial: 2003707
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of conventionally timed chemotherapy (cyclophosphamide, methotrexate, fluorouracil, prednisone) for premenopausal women or this combination plus tamoxifen for postmenopausal women
Trial: 2003707
Drug: Both perioperative
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy
Trial: 27388365
Drug: Moderately unhealthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately unhealthy oral conditions based on OHAT scores
Trial: 27388365
Drug: Unhealthy oral
RxNorm normalized name: Healthy Mama Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unhealthy oral conditions based on OHAT scores
Trial: 27388365
Drug: Moderate-to-very poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-to-very poor oral hygiene assessed by PI
Trial: 27388365
Drug: Overall oral
RxNorm normalized name: Feverall Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall oral health status
Trial: 25961461
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg anacetrapib with background treatment of placebo
Trial: 25961461
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg anacetrapib with background treatment of 20 mg atorvastatin
Trial: 16001165
Drug: Oral vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vinorelbine 70 mg/m2
Trial: 16001165
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine 30 mg/m2
Trial: 12581972
Drug: 2.0 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/ml ropivacaine (group R)
Trial: 12581972
Drug: 1.25 mg/ml
RxNorm normalized name: menthol 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/ml ropivacaine plus 1.0 microg/ml fentanyl (group RF1)
Trial: 12581972
Drug: 1.0 mg/ml
RxNorm normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/ml ropivacaine plus 2.0 microg/ml fentanyl (group RF2)
Trial: 12581972
Drug: 1.0 mg/ml
RxNorm normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/ml ropivacaine plus 4.0 microg/ml fentanyl (group RF4)
Trial: 7776420
Drug: Rufloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin 200 mg once daily (after a loading dose of 400 mg on day 1)
Trial: 25312446
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy
Trial: 26522053
Drug: Combination DOX/mCTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DOX/mCTX
Trial: 26522053
Drug: Single-agent DOX
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent DOX
Trial: 17584355
Drug: Nurse's education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse's education using short message service (SMS) for 12 weeks, including diet, exercise, medication adjustment, and self-monitoring of blood glucose levels.
Trial: 15189746
Drug: Meropenem 125
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 125 mg/h
Trial: 15189746
Drug: Meropenem 250
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 250 mg/h
Trial: 15189746
Drug: Meropenem 125
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 125 mg/h and 250 mg/h
Trial: 15189746
Drug: Meropenem continuous
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem continuous infusion
Trial: 9605374
Drug: MNS technique
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNS technique (4 injections of 10 mL each)
Trial: 9605374
Drug: TA technique
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA technique (2 injections of 20 mL each)
Trial: 2258780
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment phases
Trial: 7374099
Drug: Isotonic electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic electrolyte solution (control)
Trial: 30551540
Drug: Topical emulgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical emulgel formulation with Mimosa pudica seed extract
Trial: 20950166
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg daily injections)
Trial: 1958279
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (low-dose cyclosporin, azathioprine, methylprednisolone)
Trial: 1958279
Drug: CyA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA plus MP (double drug combination)
Trial: 1958279
Drug: Aza plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aza plus CyA (double drug combination)
Trial: 1958279
Drug: Aza plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aza plus MP (double drug combination)
Trial: 6184564
Drug: Captopril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (1 mg/kg)
Trial: 24321403
Drug: Text messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messages for medication reminders and education
Trial: 20201481
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticoagulants (direct thrombin inhibitors and direct factor Xa inhibitors)
Trial: 20201481
Drug: Conventional anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulants (warfarin and low-molecular-weight heparins)
Trial: 10399110
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg orally once daily (n = 119)
Trial: 10399110
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg orally twice daily (n = 117)
Trial: 23239048
Drug: Synbiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic mixture (2.5 × 10(9) CFU live bacteria including Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium, and 625 mg fructooligosaccharide) for 5 days
Trial: 23239048
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional hydration therapy without synbiotic)
Trial: 21215482
Drug: VIPER-BP intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIPER-BP intervention (intensive BP management strategy using valsartan-based therapy)
Trial: 18061128
Drug: Longitudinal urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal urinary creatinine excretion data
Trial: 12942142
Drug: Procyclidine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procyclidine (15 mg)
Trial: 8441428
Drug: Low-dose unilateral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unilateral electroconvulsive therapy
Trial: 8441428
Drug: High-dose unilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose unilateral electroconvulsive therapy
Trial: 8441428
Drug: Low-dose bilateral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bilateral electroconvulsive therapy
Trial: 8441428
Drug: High-dose bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bilateral electroconvulsive therapy
Trial: 8441428
Drug: Bilateral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral therapy
Trial: 8441428
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who responded to therapy
Trial: 3954009
Drug: Reflective blanket
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflective blanket and heated glycine 1.5% bladder irrigation solution
Trial: 30321510
Drug: Nebulized Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized Tranexamic Acid (500 mg tid)
Trial: 21280534
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml Mitomycin-C solution
Trial: 21280534
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Solution
Trial: 17591527
Drug: Antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drug therapy (including ACE inhibitors and ARBs)
Trial: 10221703
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pills (30 microg of ethinyl oestradiol and 0.15 mg of levonorgestrel per tablet)
Trial: 8595506
Drug: AZT/ddI and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT/ddI and AZT/ddC combination therapy
Trial: 8595506
Drug: AZT/3TC combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZT/3TC combination therapy
Trial: 2242846
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (160 mg daily for 6 weeks)
Trial: 1233231
Drug: Diazepam 20
RxNorm normalized name: diazePAM 20 mg rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 20 mg i.m. followed by diazepam 20 mg i.v.
Trial: 1233231
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg i.m. followed by diazepam 20 mg i.v.
Trial: 1233231
Drug: Pentobarbitone 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbitone 1 mg/kg i.m. followed by i.v. saline
Trial: 1233231
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg and saline i.v.
Trial: 1233231
Drug: Diazepam 20
RxNorm normalized name: diazePAM 20 mg rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 20 mg i.v.
Trial: 28723227
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine (mean final daily dose of 2.6 ± 1.1 mg, n=14)
Trial: 28723227
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine
Trial: 25222798
Drug: Gratitude intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gratitude intervention (writing work-related gratitude diaries twice a week for 4 weeks)
Trial: 25222798
Drug: Hassle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hassle intervention (writing work-related hassle diaries twice a week for 4 weeks)
Trial: 25222798
Drug: Nil-treatment (no-diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nil-treatment (no-diary group)
Trial: 23802638
Drug: Sixth-generation dental
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sixth-generation dental bonding agents (DBAs)
Trial: 23802638
Drug: Seventh-generation dental
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seventh-generation dental bonding agents (DBAs)
Trial: 23802638
Drug: Fourth-generation dental
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth-generation dental bonding agents (DBAs)
Trial: 17555901
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose Gd‐BOPTA (0.05 mmol/kg)
Trial: 17056961
Drug: Scalp nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp nerve block (SNB) with 10 mL of 0.9% saline and a 1:1 mixture of bupivacaine 0.5% and lidocaine 2%
Trial: 17056961
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg x kg(‐1) IV after dural closure
Trial: 11099280
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole)
Trial: 11099280
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics (usually haloperidol or chlorpromazine)
Trial: 1479417
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg daily for one week (Group A)
Trial: 1479417
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg daily for two weeks (Group B)
Trial: 6231893
Drug: Azapropazone 600
RxNorm normalized name: Azapropazone 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone 600 mg b.d.
Trial: 27270841
Drug: Heat therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat therapy (40.5°C bath for 60 min/session, 4-5 times/week for 8 weeks)
Trial: 1468261
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of betamethasone dipropionate cream and either a water-in-oil based moisturizing cream or lotion
Trial: 1468261
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application of betamethasone dipropionate cream
Trial: 4028806
Drug: Ketoprofen suppositories
RxNorm normalized name: ketoprofen Rectal Suppository
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen suppositories (2 X 100 mg) administered 1-hour pre-operatively
Trial: 4028806
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories administered 1-hour pre-operatively
Trial: 30674296
Drug: Topical microporous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical microporous polysaccharide hemospheres (MPH) applied to the surgical site
Trial: 17600880
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and etoposide with ondansetron, metoclopramide plus dexamethasone 8 mg i.v. per day for 3 days
Trial: 1530141
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg, 160 mg)
Trial: 1530141
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg, 20 mg)
Trial: 29774635
Drug: Aripiprazole 6-12
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 6-12 mg/day
Trial: 29774635
Drug: Aripiprazole 24-30
RxNorm normalized name: aripiprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 24-30 mg/day
Trial: 29774635
Drug: Aripiprazole (OLE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (OLE, initial dose: 2 mg/day, maintenance dose: 6-24 mg/day, max 30 mg/day)
Trial: 26571136
Drug: Zumba® fitness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zumba® fitness (1 to 2 classes of 1 hour weekly)
Trial: 15902992
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 5 g/d for 5 days)
Trial: 14602495
Drug: Radical surgery
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical surgery followed by post-operative radiation therapy (Sx+PORT) (Arm I)
Trial: 14602495
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy followed by salvage surgery (RRT+/‐SSx) (Arm II)
Trial: 10485502
Drug: DFP 25
RxNorm normalized name: DFP
DrugBank: Isoflurophate (DB00677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFP 25 mg
Trial: 10485502
Drug: DFP 50
RxNorm normalized name: DFP
DrugBank: Isoflurophate (DB00677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFP 50 mg
Trial: 9245041
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) at doses of 0.015, 0.25, 1.0, 2.0 micrograms/kg/min for 20 min each
Trial: 1744874
Drug: 2% polynoxylin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% polynoxylin powder applied daily to the groin and external genitalia
Trial: 6803377
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics (neomycin and polymyxin)
Trial: 6803377
Drug: Topical antibiotics
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotics (neomycin and polymyxin) plus systemic antibiotics (gentamicin and penicillin)
Trial: 21463114
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (one weekly injection for 4 weeks)
Trial: 12782431
Drug: rHuEPO 10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 10,000 U three times weekly
Trial: 9471024
Drug: O1COr (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O1COr (Omeprazole 20 mg once daily + Clarithromycin 250 mg twice daily + Ornidazole 500 mg twice daily)
Trial: 9471024
Drug: OCOr (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCOr (Omeprazole 20 mg twice daily + Clarithromycin 250 mg twice daily + Ornidazole 500 mg twice daily)
Trial: 9471024
Drug: OCM (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCM (Omeprazole 20 mg twice daily + Clarithromycin 250 mg twice daily + Metronidazole 500 mg twice daily)
Trial: 1610161
Drug: Rice Bubbles
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice Bubbles (0.5 g/kg body weight)
Trial: 1610161
Drug: Sustain (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustain (0.5 g/kg body weight)
Trial: 1610161
Drug: All‐Bran (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All‐Bran (0.5 g/kg body weight)
Trial: 1610161
Drug: Porridge (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porridge (0.5 g/kg body weight)
Trial: 1610161
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (0.5 g/kg body weight)
Trial: 1610161
Drug: Egg and
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg and bacon meal (0.5 g protein/kg body weight)
Trial: 3884747
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (greater than 100 mg/m2) by an eight-hour infusion
Trial: 3884747
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (greater than 100 mg/m2) by a one-hour infusion
Trial: 31103608
Drug: Metreleptin administration
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin administration (replacement doses)
Trial: 31103608
Drug: Metreleptin administration
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin administration (escalating doses)
Trial: 29349511
Drug: sham-treatment+SRP
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham-treatment+SRP